DALFAMPRIDINE | A206836 | ACTAVIS LABORATORIES FL INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Acorda Therapeutics Inc. et al v. Actavis Laboratories FL, Inc. 1 patentANDA 206836dalfampridine | D. Del. | 2015-01-23 | Terminated 2015-10-21 | — |
Acorda Therapeutics Inc. et al. v. Alkem Laboratories Ltd. et al. 4 patentsANDA 206836dalfampridine | D. Del. | 2014-07-07 | Terminated 2017-04-25 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.3928
per ea
Lowest NADAC/Unit
$0.3928
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00591253360DALFAMPRIDINE ER 10 MG TABLET | $0.3928 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.